Daraxonrasib shows promise in trials
Researchers at Memorial Sloan Kettering Cancer Center have reported promising results from early clinical trials of daraxonrasib, a targeted therapy for pancreatic cancer. The drug works by blocking a specific genetic mutation found in about 90 percent of pancreatic cancer cases. When combined with standard chemotherapy, the treatment has shown the ability to shrink tumors and extend patient survival in ways not seen with existing therapies. NBC News reported that the approach could potentially double survival rates for patients with the disease.
Pancreatic cancer's deadly toll
Pancreatic cancer is one of the deadliest forms of cancer, with a five-year survival rate of just 12 percent. It is often diagnosed at late stages because symptoms are not obvious early on. About 64,000 Americans are diagnosed with pancreatic cancer each year, and more than 50,000 die from it. Current treatment options are limited, and chemotherapy alone has modest effects. The new targeted approach represents a potential shift in how the disease is managed.
Broader applications beyond pancreatic cancer
Researchers believe the treatment could also work against other types of cancer with similar genetic profiles, including colon, ovarian, and lung cancers. The drug targets the KRAS mutation, one of the most common cancer-driving mutations across many tumor types. Additional trials are being planned to test daraxonrasib against these other cancers. If approved, the drug could become part of a new class of targeted therapies that match treatments to a patient's specific genetic profile. The US Food and Drug Administration has granted the therapy breakthrough designation to speed up the review process.